CTLA4 and melanoma: It has been reported that the monotherapy of PD1 or CTLA4 blockade has prolonged the survival of patients with various advanced tumors4, including melanoma, lymphoma, renal cell cancer, head and neck squamous cell cancer, liver cancer, lung cancer, and breast cancer.